DaronGeneStreetMD
Obstetrics & Gynecology • Tulsa, OKGynecologic Oncology
Gyn/Onc with Cancer Care Associates
Dr. Street is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12697 E 51st St
Tulsa, OK 74146Phone+1 918-505-3200Fax+1 918-505-3253
Education & Training
Loyola University Medical CenterFellowship, Gynecologic Oncology, 1994 - 1997
University of Oklahoma School of Community Medicine (Tulsa)Residency, Obstetrics and Gynecology, 1990 - 1994
University of Oklahoma College of MedicineClass of 1990
Certifications & Licensure
OK State Medical License 1991 - 2025
IL State Medical License 1994 - 1999
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Oklahoma Magazine Castle Connolly, 2009-2013
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer Start of enrollment: 2008 Sep 01
Publications & Presentations
PubMed
- 2 citationsCediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-...Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay
Journal of Clinical Oncology. 2024-12-20 - 4 citationsPhase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Onc...Larry J Copeland, Mark F Brady, Robert A Burger, William H Rodgers, Helen Q Huang
Journal of Clinical Oncology. 2022-12-10 - 51 citationsA phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncol...Robert L. Coleman, Michael W. Sill, Premal H. Thaker, David Bender, Daron Street
Gynecologic Oncology. 2015-07-01
Press Mentions
OSCRI Joins NRG Oncology to Expand Cancer ResearchJanuary 15th, 2025
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
